This same study further showed that PRAL potentiates the anti-multiple myeloma effects of bortezomib by sponging miR-210 and inhibiting its ability to repress expression of bone morphogenetic protein 2 (BMP2). The gene discussed is PRAL; the disease is plasma cell myeloma.